MCID: STR020
MIFTS: 56

Strabismus

Categories: Eye diseases, Neuronal diseases

Aliases & Classifications for Strabismus

MalaCards integrated aliases for Strabismus:

Name: Strabismus 58 12 77 56 6 45 15 74
Strabismus, Susceptibility to, 1 58 13
Strabismus, Susceptibility to 58
Susceptibility to Strabismus 30
Strabismus 1 58

Characteristics:

OMIM:

58
Inheritance:
familial, but no simple mendelian inheritance established


Classifications:



External Ids:

Disease Ontology 12 DOID:540
OMIM 58 185100
ICD9CM 36 378.7
MeSH 45 D013285
MedGen 43 C1861449

Summaries for Strabismus

OMIM : 58 Strabismus, a misalignment of the eyes also referred to as 'squint,' is one of the most common ocular disorders in humans, affecting 1 to 4% of the population. It is frequently associated with amblyopia (uniocular visual neglect) (Parikh et al., 2003). Strabismus is also a feature of several syndromes, including congenital fibrosis of extraocular muscles (see, e.g., CFEOM1; 135700), Duane retraction syndrome (126800), and chronic progressive external ophthalmoplegia with myopathy (530000). (185100)

MalaCards based summary : Strabismus, also known as strabismus, susceptibility to, 1, is related to amblyopia and ocular motility disease, and has symptoms including ophthalmoplegia, spasm of conjugate gaze and anomalies of divergence. An important gene associated with Strabismus is NALCN (Sodium Leak Channel, Non-Selective). The drugs Propofol and Sevoflurane have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and thyroid, and related phenotypes are microtropia and behavior/neurological

Wikipedia : 77 Strabismus is a condition in which the eyes do not properly align with each other when looking at an... more...

Related Diseases for Strabismus

Diseases related to Strabismus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 389)
# Related Disease Score Top Affiliating Genes
1 amblyopia 32.7 GALC PHOX2A SOBP
2 ocular motility disease 32.5 GPR143 PHOX2A VANGL2
3 pathologic nystagmus 31.4 GALC GNB1 GPR143 TYR
4 hypertelorism 30.2 FGFR2 MED13L POGZ
5 congenital nystagmus 30.1 GPR143 TYR
6 alacrima, achalasia, and mental retardation syndrome 30.0 DHX30 GNB1 MED13L MPP4
7 mechanical strabismus 12.6
8 mental retardation, anterior maxillary protrusion, and strabismus 12.5
9 ptosis, strabismus, and ectopic pupils 12.4
10 hemifacial hyperplasia with strabismus 12.3
11 speech development, delayed, with facial asymmetry, strabismus, and transverse earlobe crease 12.1
12 paralytic squint 12.1
13 ptosis strabismus diastasis 12.0
14 severe intellectual disability-hypotonia-strabismus-coarse face-planovalgus syndrome 12.0
15 exotropia 12.0
16 esotropia 12.0
17 mehes syndrome 11.8
18 mental retardation, autosomal recessive 36 11.5
19 white-sutton syndrome 11.5
20 fourth cranial nerve palsy, familial congenital 11.5
21 tukel syndrome 11.4
22 hypertropia 11.4
23 abducens nerve disease 11.4
24 crouzon syndrome 11.4
25 fibrosis of extraocular muscles, congenital, 2 11.3
26 mcpherson robertson cammarano syndrome 11.3
27 microdontia hypodontia short stature 11.3
28 singh chhaparwal dhanda syndrome 11.3
29 retinoblastoma 11.3
30 fibrosis of extraocular muscles, congenital, 1 11.3
31 brown syndrome 11.3
32 duane retraction syndrome 1 11.2
33 krauss herman holmes syndrome 11.1
34 coloboma of macula 11.1
35 farsightedness 11.1
36 oculocutaneous albinism 11.1
37 congenital toxoplasmosis 11.1
38 cyclotropia 11.1
39 hypotropia 11.1
40 fetal thalidomide syndrome 11.1
41 arthrogryposis, distal, type 5 11.0
42 cortical dysplasia, complex, with other brain malformations 1 11.0
43 naegeli-franceschetti-jadassohn syndrome 11.0
44 mental retardation, autosomal dominant 18 11.0
45 hypotonia, infantile, with psychomotor retardation 11.0
46 mental retardation, autosomal recessive 55 11.0
47 3mc syndrome 11.0
48 gatad2b-associated neurodevelopmental disorder 11.0
49 albinism, oculocutaneous, type vi 10.9
50 cerebellar ataxia, mental retardation, and dysequilibrium syndrome 1 10.9

Graphical network of the top 20 diseases related to Strabismus:



Diseases related to Strabismus

Symptoms & Phenotypes for Strabismus

Human phenotypes related to Strabismus:

33
# Description HPO Frequency HPO Source Accession
1 microtropia 33 HP:0031724

Symptoms via clinical synopsis from OMIM:

58
Eyes:
strabismus
microtropia
cyclic strabismus (periodic esotrophia)

Clinical features from OMIM:

185100

UMLS symptoms related to Strabismus:


ophthalmoplegia, spasm of conjugate gaze, anomalies of divergence

MGI Mouse Phenotypes related to Strabismus:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.93 ADGRG1 FGFR2 GALC GNB1 NALCN PCDH19
2 cellular MP:0005384 9.65 ADGRG1 FGFR2 GALC GNB1 MPP4 PCDH19
3 nervous system MP:0003631 9.5 ADGRG1 DHX30 FGFR2 GALC GNB1 GPR143

Drugs & Therapeutics for Strabismus

Drugs for Strabismus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 183)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 2078-54-8 4943
2
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
3
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Not Applicable 50-02-2 5743
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Not Applicable 1177-87-3
6
Iodine Approved, Investigational Phase 4,Not Applicable 7553-56-2 807
7
Povidone Approved Phase 4,Not Applicable 9003-39-8
8
Povidone-iodine Approved Phase 4,Not Applicable 25655-41-8
9
Dexmedetomidine Approved, Vet_approved Phase 4,Not Applicable 113775-47-6 5311068 68602
10
Rimexolone Approved Phase 4 49697-38-3 39507
11
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
12
Fluorometholone Approved, Investigational Phase 4 426-13-1 9878
13
Acetylcholine Approved, Investigational Phase 4,Phase 3,Not Applicable 51-84-3 187
14
Desflurane Approved Phase 4,Not Applicable 57041-67-5 42113
15
tannic acid Approved Phase 4,Not Applicable 1401-55-4
16
Benzocaine Approved, Investigational Phase 4,Not Applicable 1994-09-7, 94-09-7 2337
17
Midazolam Approved, Illicit Phase 4,Not Applicable 59467-70-8 4192
18
Ketamine Approved, Vet_approved Phase 4,Phase 2 6740-88-1 3821
19
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
20
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
21
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
22
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
23
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
24 Platelet Aggregation Inhibitors Phase 4,Not Applicable
25 Anesthetics, Intravenous Phase 4,Phase 2,Not Applicable
26 Anesthetics Phase 4,Phase 3,Phase 2,Not Applicable
27 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Not Applicable
28 Anesthetics, Inhalation Phase 4,Not Applicable
29 Hypnotics and Sedatives Phase 4,Phase 2,Not Applicable
30 Anesthetics, General Phase 4,Phase 2,Not Applicable
31 Anti-Infective Agents Phase 4,Not Applicable
32 Disinfectants Phase 4
33 Anti-Infective Agents, Local Phase 4,Not Applicable
34 Chlorhexidine gluconate Phase 4
35 Pharmaceutical Solutions Phase 4,Not Applicable
36 Ophthalmic Solutions Phase 4,Not Applicable
37 Analgesics Phase 4,Phase 1,Phase 2,Not Applicable
38 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Analgesics, Non-Narcotic Phase 4,Phase 1,Phase 2,Not Applicable
40 Adrenergic Agents Phase 4,Not Applicable
41 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Not Applicable
43 Anti-Inflammatory Agents Phase 4,Phase 1,Phase 2,Not Applicable
44 Autonomic Agents Phase 4,Phase 3,Not Applicable
45 Antineoplastic Agents, Hormonal Phase 4,Not Applicable
46 Hormone Antagonists Phase 4,Not Applicable
47 Gastrointestinal Agents Phase 4,Phase 1,Phase 2,Not Applicable
48
protease inhibitors Phase 4,Not Applicable
49 HIV Protease Inhibitors Phase 4,Not Applicable
50 Antiemetics Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 180)
# Name Status NCT ID Phase Drugs
1 Propofol for Treatment on Emergence Agitation Unknown status NCT02738814 Phase 4 propofol
2 Comparison of Intra Ocular Pressure After Insertion of the LMA Supreme and LMA Proseal in Pediatric Patients Unknown status NCT02508181 Phase 4
3 The Effect of Povidone-iodine Ophthalmic Surgical Prep Solution on Respiration in Children Undergoing Strabismus Surgery With General Anesthesia. Completed NCT03349515 Phase 4 Provodine-Iodine Solution;Group B will receive three drops in each eye of ophthalmic balanced salt solution.
4 Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery Completed NCT01901588 Phase 4 Dexmedetomidine
5 Ocular-hypertensive Response to Topical Steroids in Children After Bilateral Strabismus Surgery Completed NCT02816905 Phase 4 0.1 % Dexamethasone;0.1% Fluorometholone;1% Rimexolone
6 Comparison of Two Treatments for Strabismus Correction: Botulinum Toxin A Associated to Surgery and Surgery Alone Completed NCT01460355 Phase 4 Botulinum Toxin Type A;saline solution
7 The Effect of Anaesthesia Depth on Oculo-cardiac Reflex Completed NCT02379546 Phase 4 Desflurane
8 Povidone-iodine Antisepsis for Strabismus Surgery Completed NCT00461656 Phase 4 Preoperative conjunctival irrigation with 5% or 1.25% PI
9 Effects of Dexmedetomidine Premedication on Emergence Agitation After Strabismus Surgery in Children Completed NCT01895023 Phase 4 Dexmedetomidine;Midazolam;Saline
10 Intranasal Dexmedetomidine vs Midazolam-ketamine Combination for Premedication of Pediatric Patients Completed NCT02072083 Phase 4 Dexmedetomidine;Ketamine
11 Functional Effects of Botox on the Brain Using MRS and fMRI Completed NCT03373162 Phase 4 onabotulinumtoxinA
12 Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease Not yet recruiting NCT02339142 Phase 4 intravenous corticosteroids (methylprednisolone)
13 Frontalis Botulinum Toxin Not yet recruiting NCT03186001 Phase 4 Abobotulinum toxin A
14 Vision In Preschoolers Study (VIP Study) Unknown status NCT00038753 Phase 3
15 A Trial of Bifocals in Myopic Children With Esophoria Unknown status NCT00000128 Phase 3
16 Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus Completed NCT01584843 Phase 3 GSK1358820
17 Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria Completed NCT00785135 Phase 3
18 The Prism Adaptation Study (PAS) Completed NCT00000121 Phase 3
19 Amblyopia (Lazy Eye) Treatment Study Completed NCT00001864 Phase 3 Atropine
20 Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia Completed NCT00000170 Phase 3 Atropine
21 Trial to Evaluate 2 Hours of Daily Patching for Amblyopia in Children Completed NCT00091923 Phase 3
22 Orthoptic Changes Following Photorefractive Keratectomy Completed NCT01279993 Phase 3
23 Trial Comparing Patching Versus Atropine for Amblyopia in 7 to < 13 Year Olds Completed NCT00315328 Phase 3 Atropine
24 Full-time Bangerter Filters Versus Part-time Daily Patching for Moderate Amblyopia in Children Completed NCT00525174 Phase 3
25 Botox Instead of Strabismus Surgery (BISS) Recruiting NCT03459092 Phase 3 Botulinum toxin type A
26 Bupivacaine Injection of Eye Muscles to Treat Strabismus Recruiting NCT01616108 Phase 2, Phase 3 Bupivacaine
27 The Effect of Slanted Recession of Horizontal Muscle on Horizontal Strabismus With Abnormal Accommodative Convergence /Accommodation Ratio (AC/A) Recruiting NCT03555045 Phase 2, Phase 3
28 Trial of Hoya SYNC III Design Lenses Recruiting NCT03831919 Phase 2, Phase 3
29 Maternal Omega-3 Supplementation to Reduce Bronchopulmonary Dysplasia Active, not recruiting NCT02371460 Phase 3
30 Comparison of Medial Rectus Resection and Plication in Exotropic Patients Not yet recruiting NCT03768362 Phase 2, Phase 3
31 Pravastatin to Prevent Preeclampsia Not yet recruiting NCT03944512 Phase 3 Pravastatin
32 Human Milk Fortification in Extremely Preterm Infants Not yet recruiting NCT03797157 Phase 2, Phase 3
33 ASIS for Enbrel in Plaque Psoriasis Unknown status NCT02112097 Phase 1, Phase 2 Gadolinium;Gadolinium;Gadolinium;Efficacy of Enbrel subcutaneously at Week 12;Efficacy of Enbrel subcutaneously at Week 24;Efficacy of Enbrel subcutaneously at Week 36;Efficacy of Enbrel subdermally at Week 12;Efficacy of Enbrel subdermally at Week 24;Efficacy of Enbrel subdermally at Week 36;PASI 75 n(%) subcutaneously at Week 12;PASI 75 n(%) subcutaneously at Week 24;PASI 75 n(%) subcutaneously at Week 36;PASI 75 n(%) subdermally at Week 12;PASI 75 n(%) subdermally at Week 24;PASI 75 n(%) subdermally at Week 36;Adverse Reactions of Enbrel subcutaneously;Adverse Reactions of Enbrel subdermally at Week 36;Gadolinium;Gadolinium;Gadolinium
34 Grading Versus Classic Inferior Oblique Anterior Transposition in Patient With Asymmetric Dissociated Vertical Deviation Unknown status NCT03135938 Phase 1, Phase 2
35 Prevention of Complications of Eye Surgery Completed NCT00478907 Phase 2 KETAMINE, PROPOFOL, THIOPENTAL
36 Eye Muscle Surgery to Treat Congenital Nystagmus Completed NCT00001866 Phase 2
37 Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease Completed NCT02023866 Phase 2 Cysteamine Bitartrate
38 An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC) Recruiting NCT03823625 Phase 2 Nivolumab plus Ipilimumab;Platinum-based chemotherapy plus Nivolumab
39 Efficacy and Safety Trial of Sodium Valproate, in Paediatric and Adult Patients With Wolfram Syndrome Recruiting NCT03717909 Phase 2 Sodium Valproate 200Mg E/C Tablet;Sodium Valproate matched placebo
40 Effect of Intravenous Nalbuphine on Emergence Agitation Not yet recruiting NCT03470077 Phase 2 IV nalbuphine 0.1 mg/kg with induction of anesthesia.;IV nalbuphine 0.1 mg/kg at the end of surgery.
41 Study of Non-surgical Treatment Versus Observation in Asian Children With Intermittent Exotropia Terminated NCT01267500 Phase 2
42 A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease Terminated NCT02473445 Phase 2 Cysteamine Bitartrate
43 The Effect of Vision Therapy/Orthoptic on Motor & Sensory Status of the 3 to 7 Years Old Strabismic Patients Unknown status NCT00917982 Phase 1
44 Monovision for the Treatment of Diplopia Completed NCT01426672 Phase 1
45 Assessment of Fibrin Glue in Pterygium Surgery and Other Forms of External Eye Surgery Completed NCT00344201 Phase 1
46 Visual Cortex Stimulation in Patients With Amblyopia Completed NCT00097162 Phase 1
47 Dichoptic Virtual Reality Therapy for Amblyopia in Adults Terminated NCT02246556 Phase 1
48 Comparison of Propofol 1mg/kg and Propofol 0.5mg/kg for Prevention of Emergence Agitation in Children Undergoing Strabismus Surgery During Sevoflurane Anesthesia Unknown status NCT02152787 Not Applicable Injection of propofol 1.0mg/kg;propofol 0.5mg/kg;normal saline
49 Pain Medications in Children Undergoing Strabismus Surgery Unknown status NCT02789969 Not Applicable Hydromorphone;Fentanyl
50 Dexamethasone (Sterodex) Versus Loteprendol (Lotemax) Eye Drops Following Strabismus Surgery Unknown status NCT02825186 Not Applicable Loteprendol etabonate 0.5%;Dexamethasone 0.1%

Search NIH Clinical Center for Strabismus

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: strabismus

Genetic Tests for Strabismus

Genetic tests related to Strabismus:

# Genetic test Affiliating Genes
1 Susceptibility to Strabismus 30

Anatomical Context for Strabismus

MalaCards organs/tissues related to Strabismus:

42
Eye, Testes, Thyroid, Brain, Cortex, Retina, Skin

Publications for Strabismus

Articles related to Strabismus:

(show top 50) (show all 3099)
# Title Authors Year
1
Development of a core outcome set for amblyopia, strabismus and ocular motility disorders: a review to identify outcome measures. ( 30736755 )
2019
2
Prevalence of amblyopia and strabismus in Hani school children in rural southwest China: a cross-sectional study. ( 30782934 )
2019
3
Clarifications to Consider Regarding Multiple-Choice Answer Form Completion Time in Children With Amblyopia and Strabismus. ( 30844020 )
2019
4
Clarifications to Consider Regarding Multiple-Choice Answer Form Completion Time in Children With Amblyopia and Strabismus-Reply. ( 30844066 )
2019
5
Correction to: development of a core outcome set for amblyopia, strabismus and ocular motility disorders: a review to identify outcome measures. ( 30857536 )
2019
6
Functional limitations recognised by adults with amblyopia and strabismus in daily life: a qualitative exploration. ( 30957266 )
2019
7
Altered brain activity in patients with strabismus and amblyopia detected by analysis of regional homogeneity: A resting‑state functional magnetic resonance imaging study. ( 31059016 )
2019
8
Strabismus surgery for diplopia in chronic progressive external ophthalmoplegia. ( 29582258 )
2019
9
Repeat Surgery for Patients Operated in Childhood for Early-Onset Esotropia and Suffering from Persistent Residual, Recurrent or Consecutive Strabismus. ( 30999328 )
2019
10
Prevalence of Strabismus Among Children With Neurofibromatosis Type 1 Disease With and Without Optic Pathway Glioma. ( 30371910 )
2019
11
Infected conjunctival pyogenic granuloma at strabismus surgery site mimicking conjunctival abscess. ( 30930675 )
2019
12
Partial scleral buckle removal during strabismus surgery after retinal detachment repair. ( 30625364 )
2019
13
Seasonality of births in horizontal strabismus: comparison with birth seasonality in schizophrenia and other disease conditions. ( 30898179 )
2019
14
Efficacy of collagen matrix implant on adhesions in restrictive strabismus: An experimental study in a rabbit model. ( 30238619 )
2019
15
Reevaluation of Current Prism Standards With Recommendations to Increase Accuracy in the Measurement of Strabismus. ( 30240722 )
2019
16
Clinical evidence supporting the use of donor sclera as spacer material in complicated cases of strabismus surgery - retrospective evaluation of surgical results in 117 patients with thyroid-associated ophthalmopathy or congenital strabismus. ( 30284412 )
2019
17
Evidence That Leonardo da Vinci Had Strabismus. ( 30347053 )
2019
18
Altered Functional Connectivity of the Primary Visual Cortex in Adult Comitant Strabismus: A Resting-State Functional MRI Study. ( 30375900 )
2019
19
Maternal smoking during pregnancy and the risk of strabismus in offspring: a meta-analysis. ( 30402966 )
2019
20
Visual electrodiagnostics and eye movement recording - World Society of Pediatric Ophthalmology and Strabismus (WSPOS) consensus statement. ( 30574885 )
2019
21
Postoperative infection following strabismus surgery: case series and increased incidence in a single referral center. ( 30611002 )
2019
22
The impact of orbital bony or fat decompression on the outcome of strabismus surgery in patients with Graves' ophthalmopathy. ( 30646996 )
2019
23
Strabismus in Bronzino's paintings: a hallmark of a realistic painter? ( 30657125 )
2019
24
Clinical association between dental malocclusion and strabismus in adolescents: a retrospective dental cast analysis. ( 30667200 )
2019
25
Outcome of delayed adjustable strabismus surgery in children using a bow-tie optional adjustable technique. ( 30672482 )
2019
26
Commentary: Adjustable strabismus surgery. ( 30672483 )
2019
27
Reoperations in Strabismus. ( 30673099 )
2019
28
Quantitative measurement of horizontal strabismus with digital photography. ( 30682411 )
2019
29
Patient-derived questionnaire items for patient-reported outcome measures in adults with strabismus. ( 30690058 )
2019
30
Bupivacaine injection combined with recession of antagonist rectus muscle to treat sensory strabismus. ( 30730234 )
2019
31
A suspected case of anesthesia-induced rhabdomyolysis in a child undergoing strabismus surgery. ( 30735783 )
2019
32
The enigmatic strabismus of Albrecht Dürer. ( 30757950 )
2019
33
Argus II Retinal Prosthesis Implantation in a Patient With a History Of Strabismus Surgery:A Surgical Technique. ( 30768220 )
2019
34
Identification and correction of restrictive strabismus following pterygium excision surgery. ( 30771334 )
2019
35
Curation and bioinformatic analysis of strabismus genes supports functional heterogeneity and proposes candidate genes with connections to RASopathies. ( 30772522 )
2019
36
One-Year Outcome Predictors of Strabismus Surgery from Anterior Segment Optical Coherence Tomography with Multiple B-Scan Averaging. ( 30792463 )
2019
37
Fierson WM; American Academy of Pediatrics Section on Ophthalmology; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists. Screening Examination of Premature Infants for Retinopathy of Prematurity. Pediatrics. 2018;142(6):e20183061. ( 30824604 )
2019
38
Reduction of oculocardiac reflex with Tetracaine eye drop in strabismus surgery. ( 30831045 )
2019
39
An analysis of strabismus reoperations in Northern Alberta, Canada from 1995 to 2015. ( 30851782 )
2019
40
Strabismus surgery in the setting of glaucoma drainage devices in the pediatric population. ( 30885808 )
2019
41
Optical Coherence Tomography Angiography: Are There Any Changes in Measurements After Strabismus Surgery? ( 30889263 )
2019
42
Efficacy of Polytetrafluoroethylene/Polylactide-co-glycolide (PTFE/PLGA) Laminate and PTFE/PLGA Laminate Containing Slow-releasing Thalidomide in Delayed Adjustable Strabismus Surgery in a Rabbit Model. ( 30892960 )
2019
43
Vertical Strabismus - Indication of Surgical Techniques on the Inferior Rectus Muscle. ( 30913888 )
2019
44
Early Buckle Migration and Restrictive Strabismus after Successful Medical Management of Scleral Buckle Infection. ( 30951443 )
2019
45
Gene expression profile of extraocular muscles following resection strabismus surgery. ( 30953624 )
2019
46
Long-term outcomes of strabismus surgery in Mobius sequence. ( 30958093 )
2019
47
Response to Analysis of reoperation rate after strabismus surgery. ( 30975356 )
2019
48
Analysis of reoperation rate after strabismus surgery. ( 30975357 )
2019
49
Anticoagulation: a practical guide for strabismus surgeons. ( 30981895 )
2019
50
Acetaminophen to reduce postoperative nausea and vomiting in patients undergoing strabismus surgery. ( 30995326 )
2019

Variations for Strabismus

ClinVar genetic disease variations for Strabismus:

6 (show top 50) (show all 85)
# Gene Variation Type Significance SNP ID Assembly Location
1 TYR NM_000372.4(TYR): c.265T> C (p.Cys89Arg) single nucleotide variant Pathogenic rs28940877 GRCh37 Chromosome 11, 88911386: 88911386
2 TYR NM_000372.4(TYR): c.265T> C (p.Cys89Arg) single nucleotide variant Pathogenic rs28940877 GRCh38 Chromosome 11, 89178218: 89178218
3 SOX3 NM_005634.2(SOX3): c.735_737dupCGC (p.Ala248_Ser249insAla) duplication Uncertain significance rs398124211 GRCh37 Chromosome X, 139586489: 139586491
4 SOX3 NM_005634.2(SOX3): c.735_737dupCGC (p.Ala248_Ser249insAla) duplication Uncertain significance rs398124211 GRCh38 Chromosome X, 140504324: 140504326
5 DMBX1 NM_147192.2(DMBX1): c.367C> T (p.Arg123Trp) single nucleotide variant Likely pathogenic rs730882203 GRCh38 Chromosome 1, 46510953: 46510953
6 DMBX1 NM_147192.2(DMBX1): c.367C> T (p.Arg123Trp) single nucleotide variant Likely pathogenic rs730882203 GRCh37 Chromosome 1, 46976625: 46976625
7 SPART NM_001142294.1(SPART): c.1450dup (p.Thr484Asnfs) duplication Likely pathogenic rs730882198 GRCh38 Chromosome 13, 36314260: 36314260
8 SPART NM_001142294.1(SPART): c.1450dup (p.Thr484Asnfs) duplication Likely pathogenic rs730882198 GRCh37 Chromosome 13, 36888397: 36888397
9 NF1 NM_001042492.2(NF1): c.1987G> A (p.Gly663Arg) single nucleotide variant Uncertain significance rs140653372 GRCh38 Chromosome 17, 31225236: 31225236
10 NF1 NM_001042492.2(NF1): c.1987G> A (p.Gly663Arg) single nucleotide variant Uncertain significance rs140653372 GRCh37 Chromosome 17, 29552254: 29552254
11 STXBP1 NM_003165.3(STXBP1): c.364C> T (p.Arg122Ter) single nucleotide variant Pathogenic rs794727792 GRCh37 Chromosome 9, 130423419: 130423419
12 STXBP1 NM_003165.3(STXBP1): c.364C> T (p.Arg122Ter) single nucleotide variant Pathogenic rs794727792 GRCh38 Chromosome 9, 127661140: 127661140
13 PCDH19 NM_001184880.1(PCDH19): c.1091dupC (p.Tyr366Leufs) duplication Pathogenic rs758946412 GRCh37 Chromosome X, 99662505: 99662505
14 PCDH19 NM_001184880.1(PCDH19): c.1091dupC (p.Tyr366Leufs) duplication Pathogenic rs758946412 GRCh38 Chromosome X, 100407507: 100407507
15 GNB1 NM_002074.4(GNB1): c.239T> C (p.Ile80Thr) single nucleotide variant Pathogenic rs752746786 GRCh37 Chromosome 1, 1737942: 1737942
16 GNB1 NM_002074.4(GNB1): c.239T> C (p.Ile80Thr) single nucleotide variant Pathogenic rs752746786 GRCh38 Chromosome 1, 1806503: 1806503
17 MED13L t(12;19)(q24.21;q12) Translocation Pathogenic NCBI36 Chromosome 12, 114971734: 114971744
18 MED13L t(12;19)(q24.21;q12) Translocation Pathogenic NCBI36 Chromosome 19, 35769937: 35769968
19 NALCN NM_052867.3(NALCN): c.3390G> A (p.Pro1130=) single nucleotide variant Pathogenic rs869312873 GRCh37 Chromosome 13, 101742197: 101742197
20 NALCN NM_052867.3(NALCN): c.3390G> A (p.Pro1130=) single nucleotide variant Pathogenic rs869312873 GRCh38 Chromosome 13, 101089846: 101089846
21 GNB1 NM_002074.4(GNB1): c.228T> G (p.Asp76Glu) single nucleotide variant Pathogenic/Likely pathogenic rs869312822 GRCh37 Chromosome 1, 1737953: 1737953
22 GNB1 NM_002074.4(GNB1): c.284T> C (p.Leu95Pro) single nucleotide variant Pathogenic/Likely pathogenic rs869312824 GRCh37 Chromosome 1, 1736004: 1736004
23 GNB1 NM_002074.4(GNB1): c.284T> C (p.Leu95Pro) single nucleotide variant Pathogenic/Likely pathogenic rs869312824 GRCh38 Chromosome 1, 1804565: 1804565
24 GNB1 NM_002074.4(GNB1): c.228T> G (p.Asp76Glu) single nucleotide variant Pathogenic/Likely pathogenic rs869312822 GRCh38 Chromosome 1, 1806514: 1806514
25 GNB1 NM_002074.4(GNB1): c.233A> G (p.Lys78Arg) single nucleotide variant Pathogenic rs869312823 GRCh38 Chromosome 1, 1806509: 1806509
26 GNB1 NM_002074.4(GNB1): c.233A> G (p.Lys78Arg) single nucleotide variant Pathogenic rs869312823 GRCh37 Chromosome 1, 1737948: 1737948
27 RSRC2 NM_023012.5(RSRC2): c.425G> A (p.Arg142Gln) single nucleotide variant Likely pathogenic rs752134549 GRCh37 Chromosome 12, 123001951: 123001951
28 RSRC2 NM_023012.5(RSRC2): c.425G> A (p.Arg142Gln) single nucleotide variant Likely pathogenic rs752134549 GRCh38 Chromosome 12, 122517404: 122517404
29 46;XY;t(1;5)(p35.3;q31.3)dn Translocation Pathogenic
30 46;XX;t(3;12)(q13.2;q14)dn Translocation Pathogenic
31 46;XX;inv(14)(q24.1q32.1)dn inversion Uncertain significance
32 46;XY;t(6;11)(p12.3;p14.2)dn Translocation Pathogenic
33 46;XX;inv(5)(q14q33)dn inversion Uncertain significance
34 46;X;t(X;3)(p21.3;p25.1)dn Translocation Pathogenic
35 46;XX;t(6;21)(q14;q21)dn Translocation Likely pathogenic
36 46;XX;t(2;10)(q22;22.3)dn Translocation Pathogenic
37 46;XX;ins(2;9)(q24.3;p22.1p24.3)dn Translocation Pathogenic
38 FOXP1 NM_001244810.1(FOXP1): c.1396C> G (p.Pro466Ala) single nucleotide variant Likely pathogenic rs1057518926 GRCh38 Chromosome 3, 70977675: 70977675
39 FOXP1 NM_001244810.1(FOXP1): c.1396C> G (p.Pro466Ala) single nucleotide variant Likely pathogenic rs1057518926 GRCh37 Chromosome 3, 71026826: 71026826
40 SOX5 NM_006940.5(SOX5): c.482-2A> C single nucleotide variant Likely pathogenic rs1057518845 GRCh38 Chromosome 12, 23755726: 23755726
41 SOX5 NM_006940.5(SOX5): c.482-2A> C single nucleotide variant Likely pathogenic rs1057518845 GRCh37 Chromosome 12, 23908660: 23908660
42 GALC NM_000153.3(GALC): c.850G> A (p.Gly284Ser) single nucleotide variant Pathogenic/Likely pathogenic rs377274761 GRCh38 Chromosome 14, 87968393: 87968393
43 GALC NM_000153.3(GALC): c.850G> A (p.Gly284Ser) single nucleotide variant Pathogenic/Likely pathogenic rs377274761 GRCh37 Chromosome 14, 88434737: 88434737
44 GALC NM_000153.3(GALC): c.196G> A (p.Ala66Thr) single nucleotide variant Likely pathogenic rs1057518843 GRCh38 Chromosome 14, 87988523: 87988523
45 GALC NM_000153.3(GALC): c.196G> A (p.Ala66Thr) single nucleotide variant Likely pathogenic rs1057518843 GRCh37 Chromosome 14, 88454867: 88454867
46 KIF7 NM_198525.2(KIF7): c.434A> C (p.Tyr145Ser) single nucleotide variant Likely pathogenic rs758361736 GRCh37 Chromosome 15, 90193067: 90193067
47 KIF7 NM_198525.2(KIF7): c.434A> C (p.Tyr145Ser) single nucleotide variant Likely pathogenic rs758361736 GRCh38 Chromosome 15, 89649836: 89649836
48 SMARCA4 NM_001128849.1(SMARCA4): c.1358C> T (p.Thr453Ile) single nucleotide variant Likely benign rs1057518862 GRCh38 Chromosome 19, 10991262: 10991262
49 SMARCA4 NM_001128849.1(SMARCA4): c.1358C> T (p.Thr453Ile) single nucleotide variant Likely benign rs1057518862 GRCh37 Chromosome 19, 11101938: 11101938
50 MPP4 NM_033066.2(MPP4): c.946T> C (p.Trp316Arg) single nucleotide variant Pathogenic rs1057519443 GRCh37 Chromosome 2, 202539978: 202539978

Copy number variations for Strabismus from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 195555 5 152100000 155600000 Deletion AK124699 strabismus
2 195560 5 152100000 155600000 Deletion C5ORF21 strabismus
3 195565 5 152100000 155600000 Deletion C5ORF3 strabismus
4 195570 5 152100000 155600000 Deletion GALNT10 strabismus
5 195575 5 152100000 155600000 Deletion HAND1 strabismus
6 195580 5 152100000 155600000 Deletion MFAP3 strabismus
7 195585 5 152100000 155600000 Deletion NR2F1 strabismus
8 195590 5 152100000 155600000 Deletion SAP30L strabismus

Expression for Strabismus

Search GEO for disease gene expression data for Strabismus.

Pathways for Strabismus

GO Terms for Strabismus

Cellular components related to Strabismus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 melanosome membrane GO:0033162 8.62 GPR143 TYR

Biological processes related to Strabismus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cochlea development GO:0090102 9.16 SOBP VANGL2
2 membranous septum morphogenesis GO:0003149 8.96 FGFR2 VANGL2
3 eye pigment biosynthetic process GO:0006726 8.62 GPR143 TYR

Sources for Strabismus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....